fda drug safety communication naion semaglutide 2025 GLP-1 Overdoses Are Rising as Telehealth Weight-Loss Prescriptions Boom fda drug safety communication naion

adults meet the clinical criteria for obesity, and roughly 589 million people globally have diabetes over 90% of whom have type 2

The idea is that microdosing can: Reduce side effects Its common to experience side effects when taking GLP-1s, especially gastrointestinal issues including: Nausea Vomiting Diarrhea The smaller the dose, the lower the odds of side effects, so microdosing can help someone feel good enough to stay on the medication

Pushes tolerance limits for exercise

This happens because the action of semaglutide (the active ingredient in both Ozempic and Wegovy) isnt localised to act just on the fat in places we dont want it

Check your BMI in seconds Am I eligible for weight loss treatment

Coopmans, E